Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma has entered into an agreement to use its human engineering technology to humanize Aveo Pharmaceutical's AV-299, an anti-HGF monoclonal antibody which is a potential treatment for cancer.
Subscribe to our email newsletter
Aveo will pay Xoma an up-front license fee, development milestones and royalties. Aveo retains all development and commercialization rights to AV-299. More specific financial terms were not disclosed.
“Xoma's clinically-validated HE technology is intended to accelerate product development timelines for the AV-299 program, while increasing the potential for clinical and commercial success,” said Tuan Ha-Ngoc, Aveo's president and CEO.
AV-299 is a high-affinity antibody whose binding to HGF potently neutralizes the biological activities of HGF in vitro and in vivo. The HGF/c-Met pathway is frequently deregulated in different types of human cancers and is thought to play an important role in regulating tumor growth, invasion and metastasis.